You are here
Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
This consultation closed on 18 May 2021.
The Therapeutic Goods Administration (TGA) sought comments from interested parties on proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing methyl salicylate for dermal use, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposal to include advisory statements for methyl salicylate-containing medicines in RASML follows previously implemented requirements for advisory statements on labels of methyl salicylate-containing listed medicines.
For more information and to participate in the consultation, please visit consultation hub.
The consultation opened on Tuesday 6 April 2021. Interested parties responded by close of business, Tuesday 18 May 2021.
Any questions relating to submissions should be emailed to email@example.com.